You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Retrofittable and Transparent Super-Insulator for Single-Pane Windows
SBC: NANOSD, INC. Topic: DEFOA0001429NanoSD, Inc. with its partners will develop a transparent, nanostructured thermally insulating film that can be applied to existing single-pane windows to reduce heat loss. To produce the nanostructured film, the team will create hollow ceramic or polymer nanobubbles and consolidate them into a dense lattice structure using heat and compression. Because it is mostly air, the resulting nanobubble s ...
STTR Phase II 2016 Department of EnergyARPA-E -
Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of nanoscale confocal photothermal IR micro spectroscopy n CPIR
SBC: Anasys Instruments Corp. Topic: 100Abstract This proposal will lead to a Breakthrough sub cellular D chemical composition research platform for live cells based on the new invention of sub micron confocal photothermal IR micro spectroscopy CPIR Label free sub micron chemical imaging and spectroscopy has long been sought for visualization of biomolecules and materials in complex living systems Many diseases first manifest ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array
SBC: CYION TECHNOLOGIES LLC Topic: NIBIBSummary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Novel Therapeutic for Alzheimer's Disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Treatment for Traumatic Brain Injury
SBC: Epigen Biosciences, Inc. Topic: 101SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for HIV SN
SBC: WinSanTor, Inc. Topic: 101PROJECT SUMMARY Over million people worldwide including million people in the USA are HIV positive HIV associated sensory neuropathy HIV SN is the most frequent neurological manifestation of HIV and is characterized as a distal symmetrical predominantly sensory polyneuropathy HIV SN may represent clinically indistinguishable neuropathies with distinct pathogenesis a distal axona ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Production of Chemical Reagents for Prompt-Agent-Defeat Weapons
SBC: NALAS ENGINEERING SERVICES INC Topic: DTRA14B001Nalas Engineering and Johns Hopkins University collaborated in a Phase I STTR program to study reactive mixtures of HI3O8 and nanocomposite fuels previously developed by the Weihs Group. These fuel/oxidizer mixtures are uniquely able to simultaneously produce heat and biocidal iodine gas, a combination designed to destroy biological weapons. The team at Nalas focused on evaluating conditions for p ...
STTR Phase II 2017 Department of DefenseDefense Threat Reduction Agency -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel therapy for Fragile X syndrome
SBC: Epigen Biosciences, Inc. Topic: 101PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers
SBC: PROTEIN METRICS INC Topic: 400Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health